---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018426"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:37:49.117824+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q1 2024 net loss $5.4M, cash $38.4M; clinical trials advance

## Summary
- Net loss $5.4M ($0.51/share) vs $3.9M ($0.36/share) in Q1 2023; R&D expense $4.3M vs $2.6M.
- Cash, cash equivalents & marketable securities $38.4M at Mar 31, 2024, down from $41.3M at Dec 31, 2023.
- Phase 1 trials for LP-184 and LP-284 continue with no dose-limiting toxicities; LP-184 enrollment to complete summer 2024.
- Regulatory allowance granted to begin Phase 2 Harmonic trial in Japan and Taiwan for LP-300 in never-smoker NSCLC.
- ADC program advanced: novel cryptophycin-based ADC shows picomolar potency and 80% cancer cell kill rate in preclinical studies.

## SEC filing metadata
- accession: 0001493152-24-018426
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/0001493152-24-018426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018426
- JSON: https://secwatch.observer/filing/0001493152-24-018426.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018426.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for the first quarter 2024.
  - Period: the first quarter 2024
  - Result: reported results
  source text: On May 9, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/0001493152-24-018426-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.